We are live on ! Find out more
DNLI icon

Denali Therapeutics
DNLI

45 hedge funds and large institutions have $909M invested in Denali Therapeutics in 2017 Q4 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

64.56% more ownership

Funds ownership: 0% → 64.56% (+65%)

Holders
45
Holders Change
+45
Holders Change %
–
% of All Funds
1.02%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.09%
New
45
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CM
Crestline Management
Texas
+$370M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$168M
3
FP
Flagship Pioneering
Massachusetts
+$160M
4
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$88.5M
5
Temasek Holdings
Temasek Holdings
Singapore
+$79.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CM
1
Crestline Management
Texas
$322M +$370M +20,574,298 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$146M +$168M +9,344,456 New
FP
3
Flagship Pioneering
Massachusetts
$139M +$160M +8,918,749 New
Baillie Gifford & Co
4
Baillie Gifford & Co
United Kingdom
$77M +$88.5M +4,921,783 New
Temasek Holdings
5
Temasek Holdings
Singapore
$69M +$79.3M +4,410,457 New
Fidelity International
6
Fidelity International
Bermuda
$65.5M +$75.2M +4,184,982 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$14.5M +$16.7M +926,716 New
Norges Bank
8
Norges Bank
Norway
$10.2M +$11.7M +650,000 New
AI
9
Alphabet Inc
California
$8.86M +$10.2M +566,666 New
Mitsubishi UFJ Trust & Banking
10
Mitsubishi UFJ Trust & Banking
Japan
$8.48M +$9.74M +542,100 New
AG
11
Artal Group
Luxembourg
$7.82M +$8.99M +500,000 New
BAMCO Inc
12
BAMCO Inc
New York
$7.66M +$8.81M +490,000 New
BM
13
Bridger Management
New York
$4.89M +$5.62M +312,500 New
FCMI
14
Foresite Capital Management II
California
$3.91M +$4.49M +250,000 New
EC
15
EcoR1 Capital
California
$3.13M +$3.59M +200,000 New
Allianz Asset Management
16
Allianz Asset Management
Germany
$3.12M +$3.59M +199,545 New
Principal Financial Group
17
Principal Financial Group
Iowa
$2.83M +$3.25M +180,769 New
Goldman Sachs
18
Goldman Sachs
New York
$2.19M +$2.52M +139,976 New
OAM
19
Oxford Asset Management
United Kingdom
$1.85M +$2.21M +122,995 New
NTC
20
NF Trinity Capital
Hong Kong
$1.56M +$1.8M +100,000 New
FCMI
21
Foresite Capital Management IV
California
$1.48M +$1.7M +94,666 New
Millennium Management
22
Millennium Management
New York
$1.48M +$1.7M +94,316 New
LCM
23
Laurion Capital Management
New York
$1.33M +$1.53M +85,000 New
SSA
24
Schonfeld Strategic Advisors
New York
$743K +$854K +47,492 New
MWNA
25
Marshall Wace North America
New York
$709K +$815K +45,333 New
1
2

DNLI Hedge Fund Activity: Q4 2017 in Review

45 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q4 2017, worth a combined $909M.

Buyers outnumbered sellers: 45 funds opened new DNLI positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Crestline Management, opening a new position worth an estimated $370M.

  • 45 institutional investors held Denali Therapeutics (DNLI) as of Q4 2017, up from 0 in Q3 2017.
  • Funds reported $909M of Denali Therapeutics stock for Q4 2017.
  • 45 funds opened new Denali Therapeutics positions in Q4 2017 and 0 closed out, a net change of +45 holders.
  • The largest Denali Therapeutics buyer in Q4 2017 was Crestline Management, an estimated $370M added.

Based on aggregated 13F filings for Q4 2017.